Suchergebnisse - "Efe, Cumali"

PubPharm (8)

1

Letter to the Editor : Reply to Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use

enthalten in: Hepatology communications | 2022

von Efe, C. | Wahlin, S.

CommentOn: Hepatology. 2021 Jun;73(6):2099-2109. - PMID 33713486

2

Tacrolimus as second-line therapy in acute severe autoimmune hepatitis

enthalten in: Scandinavian journal of gastroenterology | 2021

von Efe, C.

CommentOn: Scand J Gastroenterol. 2020 Nov;55(11):1309-1317. - PMID 33070650

3

Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis

enthalten in: Journal of hepatology | 2021

von Wahlin, S. | Efe, C.

CommentOn: J Hepatol. 2020 Dec;73(6):1496-1506. - PMID 32707224

4

Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

enthalten in: Digestive diseases and sciences | 2018

von Efe, C. | Taii, H. | Ytting, H. | +17

5

Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

enthalten in: Digestive diseases and sciences | 2018

von Efe, C. | Taii, H. | Ytting, H. | +17

6

Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

enthalten in: Digestive diseases and sciences | 2018

von Efe, C. | Taii, H. | Ytting, H. | +17

7

Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

enthalten in: Digestive diseases and sciences | 2018

von Efe, C. | Taii, H. | Ytting, H. | +17

8

Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2017

von Efe, C. | Hagström, H. | Ytting, H. | +24

1
[1]